

TECH TOUR 2018 DIGITAL HEALTH AWARD

BIO



Dan Vahdat

Dan Vahdat is CEO of Medopad, a British healthtech company enabling connected care, headquartered in London, UK. KPMG recently named Medopad a \$1B company in the making. Multiple global press outlets have written about Medopad's recent successes in China, as well as their successful fund raise to pursue AI initiatives alongside partners such as Tencent and Johns Hopkins. Dan is an award-winning innovator in the fields of science and technology. His professional career spans from IT to medical technology including several years at Johns Hopkins in the US. Dan studied Engineering and Mathematics, after which he pursued his PhD in Bio-Engineering at Johns Hopkins and Oxford University. He left his PhD to focus on the digital healthcare revolution with Medopad.

About Medopad

Medopad is a British enterprise healthcare technology company headquartered in London. KPMG recently named Medopad a \$1B HealthTech company in the making. Medopad offers remote monitoring apps and data analytics that support stakeholders in ensuring treatments are aligned with best practice, improving outcomes and cost. The resulting data ecosystem provides the foundation for Medopad's Machine Learning and precision medicine solutions that address some of the challenges of early detection of hard to detect life threatening health conditions. Medopad is CE approved, registered with the FDA and is HIPAA compliant. Primary clients are large hospital groups and pharmaceutical companies, and since 2012, Medopad has been a supplier to the NHS. Amongst its clients are: Bayer, Johnson & Johnson, Novartis, HCA (World's largest hospital group), Barts Health (Largest NHS Trust), Royal Free (Second largest NHS Trust) and more. Its institutional investors include Bayer pharmaceutical and Bupa.